The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlpha Growth Regulatory News (ALGW)

Share Price Information for Alpha Growth (ALGW)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.20
Bid: 1.10
Ask: 1.30
Change: 0.00 (0.00%)
Spread: 0.20 (18.182%)
Open: 1.20
High: 1.20
Low: 1.20
Prev. Close: 1.20
ALGW Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Completion of Share Purchase Acquisition

6 Dec 2022 07:00

RNS Number : 6907I
Alpha Growth PLC
06 December 2022
 

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 (as amended). Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

Alpha Growth plc

("Alpha" or the "Company")

Completion of Share Purchase Acquisition

 

Alpha Growth Plc (LSE: ALGW and OTCQB: ALPGF), a leading financial services specialist in the growing life insurance and longevity asset class, is pleased to announce that it has now successfully completed its previously announced share purchase acquisition of Old Mutual International (Guernsey) Ltd, initially announced on 24 March 2022. Following completion of the acquisition, the entity is now renamed as Alpha International Life Assurance Company (Guernsey) Ltd ("AILAC")

Top 5 Points regarding the acquisition

· The acquisition is fully complete and has now been approved by both the Guernsey Financial Services Commission, as well as the South African regulator.

· The acquisition adds $275 million of AUM to Alpha, significantly increasing our total AUM to ~$700 million. Alpha's revenue will also increase significantly due to the increase in AUM. 

· Alpha will receive full revenue and EBIT contribution from 1 August 2022.

· Gobind Sahney, Jason Sutherland and Dan Gray will join the board of the acquired company.

· We have rebranded the entity to Alpha International Life Assurance Company (Guernsey) Ltd. ("AILAC")

As announced on 24 March 2022, The Guernsey based insurance company is a Category 1 international life insurer, with approximately 3,785 long-term life insurance contracts in force as of 31 December 2021.

The acquisition has a transaction value of ~$4.4m and includes all operations of the company, including its assets under management of approximately $275m as valued at 30 November 2022. The business is being acquired from a major international insurance group. 

This acquisition significantly increases Alpha's assets under management and provides an excellent platform for Alpha to offer both life insurance-based wealth management products and life insurance linked funds, either originated by Alpha or through other partners, to a broad base of European based UHNWI, family offices and institutions. 

Additionally, the life insurance company provides a good European based platform for further acquisitions. All activities are subject to regulatory approval and oversight.

AILAC specializes in providing insurance wrapped savings products to a broad retail community through independent distributors and insurance sales networks, to serve the individuals' financial planning needs, it is headquartered in Guernsey.

The Directors of the Company's subsidiary Providence Life Assurance Company (Bermuda) Ltd being Gobind Sahney, Jason Sutherland, and Dan Gray will be joining AILAC's board.

Gobind Sahney, Executive Chairman of Alpha, commented, "Our aim at Alpha is to help our clients both build and protect wealth, whilst also generating significant returns for our shareholders. The completion of this acquisition is an incredibly significant step in our goal of managing over $2 billion of AUM by 2025 and is just one of several exciting initiatives our team have been progressing."

"We are also in the final stages of completing our previously announced (on 17 November 2022) acquisition of Havelet Assignment Company Limited and I look forward to updating our shareholders in due course. With continued and ongoing market volatility caused by world events further underpinning the appeal of our uncorrelated offerings, as well as the potential for certain acquisition opportunities presenting themselves over the course of the next 12 to 18 months, there is a possibility, if all goes well, that we may beat our target of reaching $2bn of AUM by 2025."

 

** ENDS **

For more information, please visit www.algwplc.com or contact the following:

d

Alpha Growth plc

+44 (0) 20 3959 8600

Gobind Sahney, Executive Chairman

info@algwplc.com

 

Allenby Capital Limited

+44 (0) 20 3328 5656

Amrit Nahal (Sales and Corporate Broking)

Nick Athanas / Piers Shimwell (Corporate Finance)

 

UK Investor Relations - Mark Treharne

ir@algwplc.com

 

About Alpha Growth plc

Specialist in Longevity Assets

Alpha Growth plc is a financial advisory business providing specialist consultancy, advisory, and supplementary services to institutional and qualified investors globally in the multi-billion dollar market of longevity assets. Building on its well-established network, the Alpha Growth group has a unique position in the longevity asset services and investment business, as a listed entity with global reach. The group's strategy is to expand its advisory and business services via acquisitions and joint ventures in the UK and the US to attain commercial scale and provide holistic solutions to alternative institutional investors who are in need of specialised skills and unique access to deploy their financial resource in longevity assets.

Longevity Assets and Non-correlation

As a longevity asset, it is non-correlated to the real estate, equity capital and commodity markets. Its value is a function of time because as time passes the value gets closer to the face value of the policy. Hence creating a steady increase in the net asset value of the investment. This makes it highly attractive to investors wishing to counteract volatility within an investment portfolio and add yield.

Note: The Company only advises on and manages Longevity Assets that originate in the USA where the structured and life settlement market is highly regulated.

Forward Looking Statements Disclaimer

Certain statements, beliefs and opinions in this document are forward-looking, which reflect the Company's or, as appropriate, the Company's directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. Forward-looking statements contained in this document regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward- looking statements, which speak only as of the date of this document. Readers should not treat the contents of this document as advice relating to legal, taxation or investment matters, and are to make their own assessments concerning these and other consequences, including the merits of information and the risks. Readers of this announcement are advised to conduct their own due diligence and agree to be bound by the limitations of this disclaimer.

Important Notice

The content of this announcement has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 (FSMA). This announcement has been issued by and is the sole responsibility of the Company. The information in this announcement is subject to change.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQGDBDDBSGDGDL
Date   Source Headline
22nd Dec 20239:00 amRNSExpiration of Warrants
13th Dec 20237:00 amRNSAlpha International Life Receives KBRA Rating
14th Nov 20233:36 pmRNSJason Sutherland Receives Industry Recognition
9th Oct 20234:00 pmRNSHolding(s) in Company
9th Oct 20232:43 pmRNSHolding(s) in Company
29th Sep 202311:00 amRNSHalf-year Report
14th Aug 20236:29 pmRNSHolding(s) in Company
19th Jun 20237:00 amRNSResult of AGM
6th Jun 20237:00 amRNSNotice of AGM
15th May 20237:00 amRNSAcquisition of Minority Holding and Share Issuance
3rd May 20237:00 amRNSHolding(s) in Company
2nd May 20237:00 amRNS2022 Annual Report & Financial Statements
15th Mar 20237:00 amRNSWarrant Exercise and Total Voting Rights
6th Mar 20237:00 amRNS2022 Annual Recap and Fund Results
8th Feb 20234:40 pmRNSSecond Price Monitoring Extn
8th Feb 20234:35 pmRNSPrice Monitoring Extension
8th Feb 20231:10 pmRNSHolding(s) in Company
20th Jan 20232:05 pmRNSSecond Price Monitoring Extn
20th Jan 20232:00 pmRNSPrice Monitoring Extension
20th Jan 202311:05 amRNSSecond Price Monitoring Extn
20th Jan 202311:00 amRNSPrice Monitoring Extension
12th Dec 20227:00 amRNSFurther Regarding Havelet Acquisition
6th Dec 20227:00 amRNSCompletion of Share Purchase Acquisition
17th Nov 20227:00 amRNSFinancial Services Company Acquistion
27th Oct 20227:00 amRNSChange of Adviser
26th Oct 20224:41 pmRNSSecond Price Monitoring Extn
26th Oct 20224:36 pmRNSPrice Monitoring Extension
3rd Oct 20224:40 pmRNSSecond Price Monitoring Extn
3rd Oct 20224:35 pmRNSPrice Monitoring Extension
3rd Oct 20222:06 pmRNSSecond Price Monitoring Extn
3rd Oct 20222:00 pmRNSPrice Monitoring Extension
3rd Oct 202211:06 amRNSSecond Price Monitoring Extn
3rd Oct 202211:01 amRNSPrice Monitoring Extension
30th Sep 20227:00 amRNSHalf-year Report
28th Sep 20227:00 amRNSAppointment as Investment Manager/Insurance Update
12th Sep 20222:06 pmRNSSecond Price Monitoring Extn
12th Sep 20222:00 pmRNSPrice Monitoring Extension
9th Sep 20222:06 pmRNSSecond Price Monitoring Extn
9th Sep 20222:00 pmRNSPrice Monitoring Extension
8th Sep 20227:00 amRNSDirector and Personnel Announcement
3rd Aug 20227:00 amRNSHolding(s) in Company
26th Jul 20224:40 pmRNSSecond Price Monitoring Extn
26th Jul 20224:35 pmRNSPrice Monitoring Extension
20th Jun 20224:03 pmRNSResults of the Annual General Meeting
31st May 20227:00 amRNSRelease of 2021 Annual Report
27th Apr 20227:00 amRNSShareholder Information Update
24th Mar 20224:41 pmRNSSecond Price Monitoring Extn
24th Mar 20224:36 pmRNSPrice Monitoring Extension
24th Mar 20222:05 pmRNSSecond Price Monitoring Extn
24th Mar 20222:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.